GlaucomaABCNCT00376363
Ahmed Versus Baerveldt Comparison Study
A study testing Ahmed implant and Baerveldt implant in people with Glaucoma, run by University of Miami at 1 site in United States.
Trial summary
The objective of this study is to compare the long-term safety and efficacy of the Ahmed and the Baerveldt implants in patients who are undergoing aqueous shunt implant surgery for glaucoma. One eye of eligible patients will be randomized. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Glaucoma
- What is being tested?
- Ahmed implant and Baerveldt implant
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 276 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2005to Oct 2014
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 85 years, inclusive.
- Glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 18 mm Hg.
- Glaucoma drainage implant as planned surgical procedure.
- POAG with previous failed trabeculectomy or other intraocular surgery.
- Secondary glaucoma with or without previous intraocular surgery
Who cannot join
- Unwilling or unable to give consent or unwilling to accept randomization.
- Patient out of area and potentially unavailable for follow-up visits
- No light perception.
- Uveitis secondary to Juvenile Idiopathic Arthritis
- Previous cyclodestructive procedure or previous aqueous shunt device implanted in the same eye.
- Supero-temporal buckling or other external impediment to supero-temporal aqueous shunt implantation.
- Silicone oil-filled eyes or sufficient residual intraocular silicone oil to preclude supero-temporal aqueous shunt implantation.
- Vitreous sufficient to require a vitrectomy present in the anterior chamber at the time of surgery.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Miami, Bascom Palmer Eye Institute
Miami, Florida, 33136
About this study
The objective of this study is to compare the long-term safety and efficacy of the Ahmed and the Baerveldt implants in patients who are undergoing aqueous shunt implant surgery for glaucoma. One eye of eligible patients will be randomized. Outcome measures include intraocular pressure, visual acuity, visual field, number of glaucoma medications, glaucoma reoperations, and complications, including suprachoroidal hemorrhage, endophthalmitis, choroidal effusion, diplopia, corneal edema, and shunt/tube erosion.
Read the detailed description
Background and Significance
Aqueous shunt devices have traditionally been reserved for treatment of only the most refractory glaucomas. However, more recent studies have reported favorable results in comparison with trabeculectomy in medically uncontrolled glaucomas at lower risk of filtration failure. Consequently, aqueous shunt devices have been used increasingly in glaucoma drainage surgery.
There are two principal designs of implant in common use, the Ahmed glaucoma valve implant (New World Medical, Los Ranchos, CA, USA and the Baerveldt implant (Advanced Medical Optics, Santa Ana, CA, USA).
Having both evolved from the Molteno, the Ahmed and Baerveldt devices have in common a tube portion that drains aqueous humor from the anterior chamber to a plate that is implanted on the equatorial sclera. The size of plate determines the surface area of the drainage bleb.
The Ahmed and Baerveldt implants differ in two major respects. Firstly, the plate surface area of the Baerveldt 350 implant is almost double that of the Ahmed (185 mm2). Secondly, the Ahmed has a flow-restrictor that limits early hypotony without the need for additional external ligation.
We propose a randomized prospective clinical trial comparing the long-term safety and efficacy of the Ahmed glaucoma valve implant (FP-7) with the 350-mm2 Baerveldt implant (101-350) for surgical control of secondary glaucoma and primary glaucoma in eyes that have undergone previous ocular surgery.
Objective
The objective of this study is to compare the long-term safety and efficacy of the Ahmed FP-7 implant and the 350-mm2 Baerveldt implant in patients who are undergoing aqueous shunt implant surgery. Patients who qualify for the study are randomized to receive either an Ahmed FP-7 or Baerveldt BG-101-350 implant. Only one eye of a patient may be enrolled in the study.
Outcome discrimination between the two treatment groups will be made using typical measures of visual function (visual acuity and visual field), intraocular pressure, number of glaucoma medications, and glaucoma reoperations. Emphasis will also be placed on complication rates, including suprachoroidal hemorrhage, endophthalmitis, choroidal effusion, diplopia, corneal edema, and shunt/tube erosion.
Assignment
Since the purpose of this study is to compare the safety and efficacy of two surgical procedures used in the management of glaucoma, randomization techniques are used to assure an unbiased treatment assignment to patients.
Stratification:
Patients will be stratified by clinical center. At each Clinical Center, half of the patients will receive an Ahmed and half will receive a Baerveldt implant. Randomization takes place at the time the patient is enrolled in the study after informed consent is obtained.
Randomization:
A permuted variable block randomization scheme stratified by clinical center and type of glaucoma will be performed.
The following scenarios will constitute a failure in the ABC Study for the purposes of survival analysis:
- IOP > 21mmHG or < 6mmHg on 2 consecutive study visits at visits > 3 months
- IOP reduced by < 20% on 2 consecutive study visits at visits > 3 months
- Reoperation for glaucoma
- Loss of light perception vision
- Removal of implant for any reason
Clinical Procedures
Visual Acuity
Visual acuity is an important outcome variable in the ABC Study. Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Refraction is performed prior to formal measurement of visual acuity by either technique at the Qualifying Assessment and at the annual follow-up visits. Snellen visual acuity is measured at the Qualifying Assessment and at every follow-up visit.
Subjective refraction must be performed at the Qualifying Assessment and at the annual follow-up visits in order to determine best-corrected visual acuity. It is permissible to use a phoropter or trial frame to determine best-corrected Snellen visual acuity.
Slit Lamp Biomicroscopy Conjunctiva examination Cornea examination An assessment is made of the position and length of the tube in the eye. Anterior Chamber examination Iris examination Lens examination Tonometry Goldmann applanation tonometry is used to measure the intraocular pressure, except when irregular corneal astigmatism, corneal scarring, or corneal edema precludes accurate readings. In these cases, the Tono-Pen (Mentor) is used. The intraocular pressure is measured prior to pupillary dilation. Whenever possible, the intraocular pressure should be checked at the same time of the day as the Qualifying Assessment to minimize the effect of diurnal fluctuation The Tono-Pen (Mentor) is used in cases of corneal edema, corneal scarring, or irregular corneal astigmatism.
Central corneal thickness will be measured in each eye, by ultrasound pachymetry. A minimum of 5 measurements will be taken and the lowest recorded.
Motility Evaluation Gonioscopy Ophthalmoscopy Perimetry Visual field assessment is an important outcome measure in the ABC Study. Quantitative automated perimetry is performed using the Humphrey Field Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other technique that could affect vision. A visual field should be attempted in any eye that has sufficient vision to permit finger counting at two feet. Eyes with poor central vision may have an intact, off-center island of vision which may be measured with perimetry.
For the ABC Study, a 24-2 threshold test is performed in all patients using a size III white stimulus. Visual field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or full threshold strategy, but the same testing strategy must be used throughout the duration of the study. The pupil diameter should be 3 mm or greater before visual field testing is undertaken, and this may require pharmacologic dilation. Standardized refraction is performed to determine the patient's distance refraction and best-corrected visual acuity prior to visual field testing. The age appropriate plus lens is added to the distance refraction. Patient education is provided, and the instrument is set up for the test. The technician should monitor the patient during testing. Visual fields are performed preoperatively (within one month of enrollment in the study) and annually thereafter. Copies of all visual fields are faxed to the Statistical Coordinating Center for evaluation.
Surgical Procedures
The type of anesthesia is at the surgeon's discretion.
Conjunctival Flap:
An Ahmed FP-7 is used in all cases and implantation is performed in the superotemporal quadrant. A limbus-based or fornix-based conjunctival flap may be used depending on the surgeon's preference. Sufficient exposure is obtained in the superotemporal quadrant to permit placement of the Ahmed plate. A corneal traction suture or episcleral traction suture may be used to rotate the globe inferonasally to improve exposure.
Priming the Implant
A 28- or 30- gauge cannula is used to prime the Ahmed valve. Occlusion of the tube with a ligature is not permitted.
Attachment of Episcleral Plate:
The Ahmed plate is sutured to the sclera at a measured distance of 8 - 10 mm posterior to the limbus using the two fixation holes on the plate. The type of nonabsorbable suture used is of the surgeon's choice.
Preparation of Tube:
The tube is trimmed bevel-up to extend 2 to 3 mm into the anterior chamber.
Insertion of Tube into the Anterior Chamber:
A 23-gauge needle is used to enter the anterior chamber at the posterior limbus parallel to the iris plane. The Ahmed tube is inserted through this entry incision and should be well positioned in the anterior chamber away from the corneal endothelium and just above the iris. A 23-gauge needle produces an adequate entry incision for the tube without causing aqueous leakage around the tube.
Coverage of Tube:
A donor patch graft composed of donor sclera, donor cornea, or pericardium is used to cover the limbal portion of the tube. The suture selected to fixate the patch graft is of the surgeon's choice.
Conjunctival Closure:
Tenon's and conjunctiva are reapproximated to the limbus. The suture used for the conjunctival closure is determined by the surgeon in keeping with his or her usual practice.
At the surgeons discretion, a viscoelastic of his or her choice may be inserted into the anterior chamber, especially if the anterior chamber shallows after balanced salt solution is inserted.
The use of intraoperative medications is at the surgeon's discretionBaerveldt Implantation The type of anesthesia is at the surgeon's discretion.
Conjunctival Flap:
A 350-mm2 Baerveldt is used in all cases and implantation is performed in the superotemporal quadrant. A limbus-based or fornix-based conjunctival flap may be used depending on the surgeon's preference.
Scleral Exposure:
Sufficient exposure is obtained in the superotemporal quadrant to permit placement of the Baerveldt plate. A corneal traction suture or episcleral traction suture may be used to rotate the globe inferonasally and improve exposure.
Insertion of Episcleral Plate:
The 350-mm2 Baerveldt plate may be positioned under or over the superior rectus and lateral rectus muscles, depending on the surgeon's usual practice. The implant is sutured to the sclera at a measured distance of 8 - 10 mm posterior to the limbus using the two fixation holes on the plate. The type of nonabsorbable suture used is of the surgeon's choice.
Occlusion of Tube:
The Baerveldt tube must be completely occluded in all cases in order to restrict aqueous flow to the plate until it becomes encapsulated. This is done to minimize the incidence of postoperative hypotony. The method of tube occlusion is left to the discretion of the surgeon. Ligation of the tube with a polyglactin suture near the tube-plate junction, ligation with a polypropylene suture which is inserted into the anterior chamber with the tube, or internal occlusion of the tube using a "rip-cord" technique have all been used effectively. A 30-gauge cannula is used to cannulate the end of the tube and confirm complete occlusion of the tube. Following tube occlusion, the surgeon may fenestrate the tube if desired. The method of tube fenestration is left to the discretion of the surgeon.
Preparation of Tube:
The tube is trimmed bevel-up to extend 2 to 3 mm into the anterior chamber.
Insertion of Tube into the Anterior Chamber:
A 23-gauge needle is used to enter the anterior chamber at the posterior limbus parallel to the iris plane. The Baerveldt tube is inserted through this entry incision and should be well positioned in the anterior chamber away from the corneal endothelium and just above the iris. A 23-gauge needle produces an adequate entry incision for the tube without causing aqueous leakage around the tube.
Coverage of Tube:
A donor patch graft composed of donor sclera, dura mater, or pericardium is used to cover the limbal portion of the tube. The suture selected to fixate the patch graft is of the surgeon's choice.
Conjunctival Closure:
Tenon's and conjunctiva are reapproximated to the limbus. The suture used for the conjunctival closure is determined by the surgeon in keeping with his or her usual practice.
The use of intraoperative medications is at the surgeon's discretion.
Multicenter clinical trials require an organizational structure that provides efficient operations and facilitates communication. The following resource centers work together in this study:
- Clinical Centers (CC)
- Statistical Coordinating Center (SCC)
- Safety and Data Monitoring Committee (SDMC)
- Steering Committee (SC)
- Conditions
- Glaucoma
- Being tested
- Ahmed implant, Baerveldt implant
- Keywords
- glaucoma, Ahmed implant, Baerveldt implant
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ahmed implantDevice
Also called Ahmed fp7
placement of glaucoma drainage device to control intraocular pressure
Baerveldt implantDevice
Also called Baerveldt 350
placement of glaucoma drainage device to control intraocular press
| Study group | Role | What they receive |
|---|---|---|
| Ahmed implant,1 | Active comparator | Ahmed glaucoma drainage implant for intraocular pressure control Receives: Device: Ahmed implant |
| Baerveldt implant | Active comparator | Baerveldt glaucoma drainage implant for intraocular pressure control Receives: Device: Baerveldt implant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraocular Pressure
intraocular pressure mmHg at 5 years
Measured: 5 years
Failure Rate
5-year failure rate measured by Kaplan-Meier, defined as IOP>21 mm Hg or less than a 20% reduction below baseline on 2 consecutive study visits after 3 months, reoperation for glaucoma, loss of light perception, or removal of implant
Measured: 5 years
Secondary outcomes (1)
Visual Acuity
Snellen chart converted to logMAR (smaller logMAR values indicate better visual acuity logMar of 0 is Snellen 20/20; logMAR of 20/200 is 1.0)
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2006 (estimated)
- Study startNov 2005
- Primary completionDec 2013
- Study completionOct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by University of MiamiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 276 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Miami
- Sponsor type
- University, hospital or other
- Collaborators
- National Eye Institute (NEI), Research to Prevent Blindness
- Responsible party
- Principal investigator, Donald L. Budenz, University of North Carolina, Chapel Hill
- Investigators
- Donald L Budenz, M.D.,M.P.H., Principal investigator, University of North CarolinaKeith Barton, M.D., Principal investigator, Moorfields Eye Hospital NHS Foundation TrustWilliam J Feuer, M.S., Principal investigator, University of Miami
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00376363
- Sponsor's protocol ID
- 20057138
- Other IDs
- P30EY014801
- Acronym
- ABC
- Status last verified
- Jul 2015
- First submitted
- 13 Sep 2006
- Last updated
- 20 Aug 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, Bacharach J, Panek WC. Initial clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1995 Jul;120(1):23-31. doi: 10.1016/s0002-9394(14)73755-9.
PubMed 7611326Topouzis F, Coleman AL, Choplin N, Bethlem MM, Hill R, Yu F, Panek WC, Wilson MR. Follow-up of the original cohort with the Ahmed glaucoma valve implant. Am J Ophthalmol. 1999 Aug;128(2):198-204. doi: 10.1016/s0002-9394(99)00080-x.
PubMed 10458176Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, LaBree L, Heuer DK. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994 Aug;101(8):1456-63; discussion 1463-4. doi: 10.1016/s0161-6420(94)31152-3.
PubMed 8058290Britt MT, LaBree LD, Lloyd MA, Minckler DS, Heuer DK, Baerveldt G, Varma R. Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: is bigger better? Ophthalmology. 1999 Dec;106(12):2312-8. doi: 10.1016/S0161-6420(99)90532-8.
PubMed 10599663Wang JC, See JL, Chew PT. Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population. Ophthalmology. 2004 Jul;111(7):1383-8. doi: 10.1016/j.ophtha.2003.11.005.
PubMed 15234141Tsai JC, Johnson CC, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome. Ophthalmology. 2003 Sep;110(9):1814-21. doi: 10.1016/S0161-6420(03)00574-8.
PubMed 13129882Nguyen QH, Budenz DL, Parrish RK 2nd. Complications of Baerveldt glaucoma drainage implants. Arch Ophthalmol. 1998 May;116(5):571-5. doi: 10.1001/archopht.116.5.571.
PubMed 9596491Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J; Ahmed Baerveldt Comparison Study Group. The Ahmed Baerveldt Comparison Study methodology, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011 Mar;118(3):435-42. doi: 10.1016/j.ophtha.2010.07.015. Epub 2010 Oct 8.
PubMed 20932581Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology. 2011 Mar;118(3):443-52. doi: 10.1016/j.ophtha.2010.07.016. Epub 2010 Oct 8.
PubMed 20932583Barton K, Feuer WJ, Budenz DL, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2014 Aug;121(8):1547-57.e1. doi: 10.1016/j.ophtha.2014.01.036. Epub 2014 Apr 24.
PubMed 24768240Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015 Feb;122(2):308-16. doi: 10.1016/j.ophtha.2014.08.043. Epub 2014 Oct 17.
PubMed 25439606
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ahmed Versus Baerveldt Comparison Study
- ClinicalTrials.gov ID
- NCT00376363
- Acronym / sponsor ID
- ABC / 20057138
- Conditions
- Glaucoma
- Keywords
- glaucoma, Ahmed implant, Baerveldt implant
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 276 participants (actual)
- Lead sponsor
- University of MiamiUniversity, hospital or other
- Collaborators
- National Eye Institute (NEI), Research to Prevent Blindness
- Study start
- Nov 2005
- Primary completion
- Dec 2013 (actual)
- Study completion
- Oct 2014 (actual)
- First posted
- 14 Sep 2006 (estimated)
- Results
- Posted 4 Jun 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to compare the long-term safety and efficacy of the Ahmed and the Baerveldt implants in patients who are undergoing aqueous shunt implant surgery for glaucoma. One eye of eligible patients will be randomized. Outcome measures include intraocular pressure, visual acuity, visual field, number of glaucoma medications, glaucoma reoperations, and complications, including suprachoroidal hemorrhage, endophthalmitis, choroidal effusion, diplopia, corneal edema, and shunt/tube erosion.
Detailed description
Background and Significance
Aqueous shunt devices have traditionally been reserved for treatment of only the most refractory glaucomas. However, more recent studies have reported favorable results in comparison with trabeculectomy in medically uncontrolled glaucomas at lower risk of filtration failure. Consequently, aqueous shunt devices have been used increasingly in glaucoma drainage surgery.
There are two principal designs of implant in common use, the Ahmed glaucoma valve implant (New World Medical, Los Ranchos, CA, USA and the Baerveldt implant (Advanced Medical Optics, Santa Ana, CA, USA).
Having both evolved from the Molteno, the Ahmed and Baerveldt devices have in common a tube portion that drains aqueous humor from the anterior chamber to a plate that is implanted on the equatorial sclera. The size of plate determines the surface area of the drainage bleb.
The Ahmed and Baerveldt implants differ in two major respects. Firstly, the plate surface area of the Baerveldt 350 implant is almost double that of the Ahmed (185 mm2). Secondly, the Ahmed has a flow-restrictor that limits early hypotony without the need for additional external ligation.
We propose a randomized prospective clinical trial comparing the long-term safety and efficacy of the Ahmed glaucoma valve implant (FP-7) with the 350-mm2 Baerveldt implant (101-350) for surgical control of secondary glaucoma and primary glaucoma in eyes that have undergone previous ocular surgery.
Objective
The objective of this study is to compare the long-term safety and efficacy of the Ahmed FP-7 implant and the 350-mm2 Baerveldt implant in patients who are undergoing aqueous shunt implant surgery. Patients who qualify for the study are randomized to receive either an Ahmed FP-7 or Baerveldt BG-101-350 implant. Only one eye of a patient may be enrolled in the study.
Outcome discrimination between the two treatment groups will be made using typical measures of visual function (visual acuity and visual field), intraocular pressure, number of glaucoma medications, and glaucoma reoperations. Emphasis will also be placed on complication rates, including suprachoroidal hemorrhage, endophthalmitis, choroidal effusion, diplopia, corneal edema, and shunt/tube erosion.
Assignment
Since the purpose of this study is to compare the safety and efficacy of two surgical procedures used in the management of glaucoma, randomization techniques are used to assure an unbiased treatment assignment to patients.
Stratification:
Patients will be stratified by clinical center. At each Clinical Center, half of the patients will receive an Ahmed and half will receive a Baerveldt implant. Randomization takes place at the time the patient is enrolled in the study after informed consent is obtained.
Randomization:
A permuted variable block randomization scheme stratified by clinical center and type of glaucoma will be performed.
The following scenarios will constitute a failure in the ABC Study for the purposes of survival analysis:
- IOP > 21mmHG or < 6mmHg on 2 consecutive study visits at visits > 3 months
- IOP reduced by < 20% on 2 consecutive study visits at visits > 3 months
- Reoperation for glaucoma
- Loss of light perception vision
- Removal of implant for any reason
Clinical Procedures
Visual Acuity
Visual acuity is an important outcome variable in the ABC Study. Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Refraction is performed prior to formal measurement of visual acuity by either technique at the Qualifying Assessment and at the annual follow-up visits. Snellen visual acuity is measured at the Qualifying Assessment and at every follow-up visit.
Subjective refraction must be performed at the Qualifying Assessment and at the annual follow-up visits in order to determine best-corrected visual acuity. It is permissible to use a phoropter or trial frame to determine best-corrected Snellen visual acuity.
Slit Lamp Biomicroscopy Conjunctiva examination Cornea examination An assessment is made of the position and length of the tube in the eye. Anterior Chamber examination Iris examination Lens examination Tonometry Goldmann applanation tonometry is used to measure the intraocular pressure, except when irregular corneal astigmatism, corneal scarring, or corneal edema precludes accurate readings. In these cases, the Tono-Pen (Mentor) is used. The intraocular pressure is measured prior to pupillary dilation. Whenever possible, the intraocular pressure should be checked at the same time of the day as the Qualifying Assessment to minimize the effect of diurnal fluctuation The Tono-Pen (Mentor) is used in cases of corneal edema, corneal scarring, or irregular corneal astigmatism.
Central corneal thickness will be measured in each eye, by ultrasound pachymetry. A minimum of 5 measurements will be taken and the lowest recorded.
Motility Evaluation Gonioscopy Ophthalmoscopy Perimetry Visual field assessment is an important outcome measure in the ABC Study. Quantitative automated perimetry is performed using the Humphrey Field Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other technique that could affect vision. A visual field should be attempted in any eye that has sufficient vision to permit finger counting at two feet. Eyes with poor central vision may have an intact, off-center island of vision which may be measured with perimetry.
For the ABC Study, a 24-2 threshold test is performed in all patients using a size III white stimulus. Visual field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or full threshold strategy, but the same testing strategy must be used throughout the duration of the study. The pupil diameter should be 3 mm or greater before visual field testing is undertaken, and this may require pharmacologic dilation. Standardized refraction is performed to determine the patient's distance refraction and best-corrected visual acuity prior to visual field testing. The age appropriate plus lens is added to the distance refraction. Patient education is provided, and the instrument is set up for the test. The technician should monitor the patient during testing. Visual fields are performed preoperatively (within one month of enrollment in the study) and annually thereafter. Copies of all visual fields are faxed to the Statistical Coordinating Center for evaluation.
Surgical Procedures
The type of anesthesia is at the surgeon's discretion.
Conjunctival Flap:
An Ahmed FP-7 is used in all cases and implantation is performed in the superotemporal quadrant. A limbus-based or fornix-based conjunctival flap may be used depending on the surgeon's preference. Sufficient exposure is obtained in the superotemporal quadrant to permit placement of the Ahmed plate. A corneal traction suture or episcleral traction suture may be used to rotate the globe inferonasally to improve exposure.
Priming the Implant
A 28- or 30- gauge cannula is used to prime the Ahmed valve. Occlusion of the tube with a ligature is not permitted.
Attachment of Episcleral Plate:
The Ahmed plate is sutured to the sclera at a measured distance of 8 - 10 mm posterior to the limbus using the two fixation holes on the plate. The type of nonabsorbable suture used is of the surgeon's choice.
Preparation of Tube:
The tube is trimmed bevel-up to extend 2 to 3 mm into the anterior chamber.
Insertion of Tube into the Anterior Chamber:
A 23-gauge needle is used to enter the anterior chamber at the posterior limbus parallel to the iris plane. The Ahmed tube is inserted through this entry incision and should be well positioned in the anterior chamber away from the corneal endothelium and just above the iris. A 23-gauge needle produces an adequate entry incision for the tube without causing aqueous leakage around the tube.
Coverage of Tube:
A donor patch graft composed of donor sclera, donor cornea, or pericardium is used to cover the limbal portion of the tube. The suture selected to fixate the patch graft is of the surgeon's choice.
Conjunctival Closure:
Tenon's and conjunctiva are reapproximated to the limbus. The suture used for the conjunctival closure is determined by the surgeon in keeping with his or her usual practice.
At the surgeons discretion, a viscoelastic of his or her choice may be inserted into the anterior chamber, especially if the anterior chamber shallows after balanced salt solution is inserted.
The use of intraoperative medications is at the surgeon's discretionBaerveldt Implantation The type of anesthesia is at the surgeon's discretion.
Conjunctival Flap:
A 350-mm2 Baerveldt is used in all cases and implantation is performed in the superotemporal quadrant. A limbus-based or fornix-based conjunctival flap may be used depending on the surgeon's preference.
Scleral Exposure:
Sufficient exposure is obtained in the superotemporal quadrant to permit placement of the Baerveldt plate. A corneal traction suture or episcleral traction suture may be used to rotate the globe inferonasally and improve exposure.
Insertion of Episcleral Plate:
The 350-mm2 Baerveldt plate may be positioned under or over the superior rectus and lateral rectus muscles, depending on the surgeon's usual practice. The implant is sutured to the sclera at a measured distance of 8 - 10 mm posterior to the limbus using the two fixation holes on the plate. The type of nonabsorbable suture used is of the surgeon's choice.
Occlusion of Tube:
The Baerveldt tube must be completely occluded in all cases in order to restrict aqueous flow to the plate until it becomes encapsulated. This is done to minimize the incidence of postoperative hypotony. The method of tube occlusion is left to the discretion of the surgeon. Ligation of the tube with a polyglactin suture near the tube-plate junction, ligation with a polypropylene suture which is inserted into the anterior chamber with the tube, or internal occlusion of the tube using a "rip-cord" technique have all been used effectively. A 30-gauge cannula is used to cannulate the end of the tube and confirm complete occlusion of the tube. Following tube occlusion, the surgeon may fenestrate the tube if desired. The method of tube fenestration is left to the discretion of the surgeon.
Preparation of Tube:
The tube is trimmed bevel-up to extend 2 to 3 mm into the anterior chamber.
Insertion of Tube into the Anterior Chamber:
A 23-gauge needle is used to enter the anterior chamber at the posterior limbus parallel to the iris plane. The Baerveldt tube is inserted through this entry incision and should be well positioned in the anterior chamber away from the corneal endothelium and just above the iris. A 23-gauge needle produces an adequate entry incision for the tube without causing aqueous leakage around the tube.
Coverage of Tube:
A donor patch graft composed of donor sclera, dura mater, or pericardium is used to cover the limbal portion of the tube. The suture selected to fixate the patch graft is of the surgeon's choice.
Conjunctival Closure:
Tenon's and conjunctiva are reapproximated to the limbus. The suture used for the conjunctival closure is determined by the surgeon in keeping with his or her usual practice.
The use of intraoperative medications is at the surgeon's discretion.
Multicenter clinical trials require an organizational structure that provides efficient operations and facilitates communication. The following resource centers work together in this study:
- Clinical Centers (CC)
- Statistical Coordinating Center (SCC)
- Safety and Data Monitoring Committee (SDMC)
- Steering Committee (SC)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ahmed implant,1 | Active comparator | Device: Ahmed implantAhmed glaucoma drainage implant for intraocular pressure control |
| Baerveldt implant | Active comparator | Device: Baerveldt implantBaerveldt glaucoma drainage implant for intraocular pressure control |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18 to 85 years, inclusive.
- Glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 18 mm Hg.
- Glaucoma drainage implant as planned surgical procedure.
- POAG with previous failed trabeculectomy or other intraocular surgery.
- Secondary glaucoma with or without previous intraocular surgery
Key exclusion criteria (8 listed)
- Unwilling or unable to give consent or unwilling to accept randomization.
- Patient out of area and potentially unavailable for follow-up visits
- No light perception.
- Uveitis secondary to Juvenile Idiopathic Arthritis
- Previous cyclodestructive procedure or previous aqueous shunt device implanted in the same eye.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ahmed implantAlso: Ahmed fp7placement of glaucoma drainage device to control intraocular pressure | Device | Ahmed implant,1 |
| Baerveldt implantAlso: Baerveldt 350placement of glaucoma drainage device to control intraocular press | Device | Baerveldt implant |
Primary outcome
Intraocular Pressure
Time frame: 5 years
intraocular pressure mmHg at 5 years
Failure Rate
Time frame: 5 years
5-year failure rate measured by Kaplan-Meier, defined as IOP>21 mm Hg or less than a 20% reduction below baseline on 2 consecutive study visits after 3 months, reoperation for glaucoma, loss of light perception, or removal of implant
1 secondary outcome
Visual Acuity
Time frame: 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 7611326Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, Bacharach J, Panek WC. Initial clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1995 Jul;120(1):23-31. doi: 10.1016/s0002-9394(14)73755-9.
- Background: PubMed 10458176Topouzis F, Coleman AL, Choplin N, Bethlem MM, Hill R, Yu F, Panek WC, Wilson MR. Follow-up of the original cohort with the Ahmed glaucoma valve implant. Am J Ophthalmol. 1999 Aug;128(2):198-204. doi: 10.1016/s0002-9394(99)00080-x.
- Background: PubMed 8058290Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, LaBree L, Heuer DK. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994 Aug;101(8):1456-63; discussion 1463-4. doi: 10.1016/s0161-6420(94)31152-3.
- Background: PubMed 10599663Britt MT, LaBree LD, Lloyd MA, Minckler DS, Heuer DK, Baerveldt G, Varma R. Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: is bigger better? Ophthalmology. 1999 Dec;106(12):2312-8. doi: 10.1016/S0161-6420(99)90532-8.
- Background: PubMed 15234141Wang JC, See JL, Chew PT. Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population. Ophthalmology. 2004 Jul;111(7):1383-8. doi: 10.1016/j.ophtha.2003.11.005.
- Background: PubMed 13129882Tsai JC, Johnson CC, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome. Ophthalmology. 2003 Sep;110(9):1814-21. doi: 10.1016/S0161-6420(03)00574-8.
- Background: PubMed 9596491Nguyen QH, Budenz DL, Parrish RK 2nd. Complications of Baerveldt glaucoma drainage implants. Arch Ophthalmol. 1998 May;116(5):571-5. doi: 10.1001/archopht.116.5.571.
- Results publication: PubMed 20932581Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J; Ahmed Baerveldt Comparison Study Group. The Ahmed Baerveldt Comparison Study methodology, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011 Mar;118(3):435-42. doi: 10.1016/j.ophtha.2010.07.015. Epub 2010 Oct 8.
- Results publication: PubMed 20932583Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology. 2011 Mar;118(3):443-52. doi: 10.1016/j.ophtha.2010.07.016. Epub 2010 Oct 8.
- Results publication: PubMed 24768240Barton K, Feuer WJ, Budenz DL, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2014 Aug;121(8):1547-57.e1. doi: 10.1016/j.ophtha.2014.01.036. Epub 2014 Apr 24.
- Results publication: PubMed 25439606Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015 Feb;122(2):308-16. doi: 10.1016/j.ophtha.2014.08.043. Epub 2014 Oct 17.
Related trials for Glaucoma
Recruiting
Effects of Balance Training in Individuals With Glaucoma
Glaucoma
Not yet recruiting
Glaucoma Drop Aids Part 2
Glaucoma, Intraocular Pressure
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingObservational study
Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery Patients
Cataract, Primary Angle-Closure Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Donald L Budenz, M.D.,M.P.H. principal investigator
University of North Carolina
Keith Barton, M.D. principal investigator
Moorfields Eye Hospital NHS Foundation Trust
William J Feuer, M.S. principal investigator
University of Miami
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ahmed implant and Baerveldt implant in people with Glaucoma, run by University of Miami at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Jun 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraocular Pressure (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00376363, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2015.